Stephen E. Gitelman, M.D.

Professor of Clinical Pediatrics; Mary B. Olney MD / KAK Chair in Pediatric Diabetes and Clinical Research
Stephen E. Gitelman, M.D.

Dr. Gitelman's research interests include type 1 and type 2 diabetes, especially issues related to children and adolescents. On-going research studies include:

  • Prevention of type 1 diabetes mellitus, including: a) participation in NIH-sponsored studies such as TrialNet to better understand the natural history and prevent type 1 diabetes, and b) the use of novel immunomodulatory agents at diagnosis to prolong endogenous insulin secretion (the honeymoon phase), such as with a humanized anti-CD3 monoclonal antibody and anti-thymocyte globulin.
  • Use of insulin pump therapy, continuous glucose sensors, and other evolving technologies to optimize metabolic control for children with diabetes
  • Improving outcomes for Latino youth with diabetes
  • Prevention of type 2 diabetes in obese adolescents
  • Post-transplantation diabetes in children

Selected Publications

2005 Herold KC, Bisikirska B, Gitelman SE, Masharani U, Hagopian W, Donaldson D, Rother K, Diamond B, Harlan D, Bluestone JA. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54: 1763-9.
2005 Wilson DM, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gitelman SE. A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care 28: 15-19.
2002 Herold KC, Hagopian W, Auger J, Poumain-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan D, Xu D, Zivin R, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med, 346: 1692-1698.
2002 Diabetes Prevention Trial – Type 1 Study Group[Gitelman SE—Study Group Member]. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med, 346: 1685-1691b.
2005 Diabetes Prevention Trial – Type 1 Study Group[Gitelman SE—Study Group Member]. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 28: 1068-1076.
2002 Greenspan LC, Gitelman SE, Mathias R. Increased incidence in post-transplant diabetes mellitus in children: a case-control analysis. Pediatric Nephrology, 17:1-5.
2004 Steele C., Hagopian, WA, Gitelman SE, Masharani U, Cavaghan M, Rother K, Donaldson, D, Harlan D, Bluestone J, Herold KC. Insulin secretion in type 1 diabetes. Diabetes 53: 426-33.
2005 Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abedini M, Lustig RH, Mathias RS, Portale AA, Miller WL, Gitelman SE. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 352: 1884-1890.
2005 Huang E, Feldman B, Geller D, Schwartz D, Gitelman SE. Oral urea for the treatment of chronic syndrome of inappropriate antidiuresis in children. J Pediatrics, in press.
2005 Sapru A, Gitelman SE, Bhatia S, Dubin R, Flori H. Prevalence and characteristics of type 2 diabetes mellitus in 9-18 year-old children with diabetic ketoacidosis. J Pediatric Endocrinol Metab, In press.
Stephen E. Gitelman, M.D.
(415) 476-3748
(415) 476-8214

eUpdate Newsletter

 
//